Researchers found that Adipotide, also known as FTPP, successfully starved fat cells of oxygen and nutrients, causing them to die and be reabsorbed by the body as a weight reduction therapy. FTPP Adipotide peptide is a weight loss and cancer prevention supplement developed in 2011 by Dr. Wadih Arap and Renata Pasqualini.
Findings suggest that Adipotide, a novel, and exciting new medication, has considerable potential for treating obesity. Animal studies have indicated that Adipotide peptide, developed as a cancer treatment to target cancer cells in the hopes that they would stop growing, may also reduce body weight.
Explaining Adipotide’s Mechanism of Action
The peptide FTPP is an illusion. That is to say, it consists of two parts that act on prohibitins (PHBs) as a whole. Rats used in the study lost 30 percent of their body weight. Ten overweight female rhesus monkeys lost around 11% of their body weight and about 40% of their fat deposits after receiving daily injections of Adipotide for four weeks, followed by four weeks without therapy. The majority of this loss occurred before and during the treatment gap.
Adipotide’s Benefits and Drawbacks
Current scientific studies have suggested several advantages of Adipotide. It has been demonstrated to promote weight reduction, and evidence indicates it may help destroy cancer cells by cutting off their blood supply. Let’s look at the perks of Adipotide and the drawbacks that make it less desirable.
The advantages of Adipotide that studies have shown are:
- The adipotide peptide has been the pinpoint of many investigations, with some encouraging results.
- Reduces fat and helps animals lose weight, according to studies.
- It cuts blood flow to fat cells, preventing animals from gaining weight.
- Animal studies confirmed that the medication’s effects on weight reduction persisted long after researchers stopped administration.
- Adipotide may lead to fluid loss.
- Lesion formation in the kidneys has been shown in experimental animals.
- It has not yet passed its beta testing phase.
Weight Loss with Adipotide
Adipotide has been showing promising outcomes in studies since at least 2011. Researchers at the University of Cincinnati College of Medicine have shown that Adipotide may help reduce body fat by signaling to the brain’s reward and reward-related areas that the body can no longer store fat.
Although Adipotide has shown promise in tests, several issues still need to be addressed before patients can widely use it. It was tested on lean monkeys and found ineffectual, indicating that the peptide’s effects may plateau at a specific BMI.
Animal studies have also shown the possibility of serious adverse effects, such as dehydration and tiny kidney lesions. While promising as a medicine for treating obesity, further study is needed on this peptide therapy before it can be made available to the public. At this time, only use for scientific study is permitted.
Evaluating Adipotide for Use in 2022 and Beyond
Adipotide peptide is an investigational peptidomimetic medication that has resulted in fast weight reduction in rodents and primates. Researchers have shown that the Adipotide procedure may selectively reduce blood vessels, leading to apoptosis in those arteries’ fat cells.
Although Adipotide has been the subject of extensive research into its potential benefits, the FDA has not yet given its blessing to the medication. This is because there is not enough proof that it is safe to do so. There is data suggesting that Adipotide dosage isn’t always the safest option.
For more information about this topic, click here.